AAV9 Gene Therapy for Juvenile Batten Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Juvenile neuronal ceroid lipofuscinosis (JNCL), also known as Juvenile Batten Disease, is a fatal neurodegenerative disorder caused by mutations in the CLN3 gene, leading to abnormal intracellular accumulation of lipid and protein in lysosomes, resulting in progressive neuronal cell death and no current effective treatment.
Innovation Solution
The use of adeno-associated viral (AAV) constructs, specifically self-complementary AAV9 constructs, to express the human CLN3 gene in the brain and other key tissues, driven by promoters like MeCP2 to achieve low-level expression, which helps restore normal CLN3 function and reduce lysosomal inclusions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If AAV constructs are used to deliver CLN3 gene to restore function, then therapeutic benefit is achieved, but precise control of expression level is required to avoid toxicity
Solution Approach 1:
The patent employs different promoter elements with varying strengths (weak, moderate, strong promoters) to precisely control the expression level of CLN3 gene. By selecting appropriate promoter strength, the invention achieves therapeutic benefit while avoiding toxicity associated with overexpression, thus resolving the contradiction between reliability and device complexity.
Solution Approach 2:
The invention uses low-level expression of CLN3 gene through weak promoters, which is sufficient to restore lysosomal function and reduce storage material accumulation without causing the harmful effects of high-level expression. This partial action approach achieves therapeutic benefit while maintaining safety.
2Reliability
If high level CLN3 expression is achieved, then gene function restoration is enhanced, but cellular toxicity increases
Solution Approach 1:
The patent systematically varies promoter strength to optimize CLN3 expression levels. Weak promoters produce low-level expression that restores sufficient gene function without reaching toxic thresholds, while strong promoters are avoided despite their ability to achieve complete function restoration. This parameter optimization resolves the contradiction between gene function restoration and cellular toxicity.
Solution Approach 2:
The invention converts the potential harm of overexpression into benefit by deliberately using sub-maximal expression levels. The weak promoter-driven low-level expression is sufficient to restore lysosomal function and clear storage material, transforming what could be a harmful condition (incomplete restoration) into a beneficial outcome (safe and effective therapy).
3Reliability
If CLN3 expression is restored in sufficient CNS cells, then therapeutic effect is achieved, but delivery system complexity increases
Solution Approach 1:
The patent uses adeno-associated virus (AAV) vectors that can broadly transduce various cell types in the central nervous system. The AAV system serves multiple functions: it delivers the CLN3 gene across different CNS cell types, provides long-term expression, and can be administered systemically. This universal delivery approach achieves therapeutic effect in sufficient cells without requiring complex cell-type-specific delivery systems.
Data Source
AI summary
Compositions and methods for the treatment of Juvenile Neuronal Ceroid Lipofuscinosis (JNCL), also known as Juvenile Batten Disease, are provided herein. In certain embodiments the compositions include but are not limited to adeno-associated viral (AAV) constructs, including self-complementary adeno-associated viral (sc-AAV) constructs, that express the human gene CLN3 (or a CLN3 cDNA).